Skip to search formSkip to main contentSkip to account menu

LGX818

Known as: Raf Kinase Inhibitor LGX818 
An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

encorafenib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib…
Background: Although BRAF V600-mutated (BRAFm) colorectal carcinoma (CRC) does not generally respond to BRAF inhibitors, results… 
2015
2015
Successful implementation of a novel trial model: The Signature program.
106 Background: Here we describe 8 ongoing single agent clinical protocols under Novartis’ “Signature” program involving… 
2015
2015
Drug combo beneficial in colorectal cancer.
The BRAF V600E mutation, well documented in melanoma, is also present in approximately 8% of patients with colorectal cancer… 
2015
2015
Abstract 2140: Dual Wnt and EGFR-MAPK dependency ofBRAFV600E-mutant colorectal cancer
Aberrant Wnt pathway activation due to inactivating mutations in the gene encoding RNF43 (an E3 ubiquitin ligase that promotes… 
2014
2014
Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA RAF kinase inhibitors have shown substantial therapeutic… 
2014
2014
11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced…
2014
2014
Highlights of melanoma research presented at the 49th annual meeting of the American Society of Clinical Oncology in Chicago, 2013
No: 9010). This antibody exhibited much lower toxicity in patients with melanoma (n = 45) than the anti-PD1 and anti-CTLA-4… 
2014
2014
Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.
9062 Background: The BRAF inhibitors vemurafenib and dabrafenib have demonstrated antitumor activity in patients with metastatic… 
2014
2014
The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma
2012
2012
Abstract 5592: Modeling the evolution of resistance to RAF inhibitors in clinically relevant melanoma models
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Small molecule RAF inhibitors such as Vemurafenib… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)